Literature DB >> 16131330

Physiology and pathophysiology of type 3 deiodinase in humans.

Stephen A Huang1.   

Abstract

Type 3 iodothyronine deiodinase (D3) is the physiologic inactivator of thyroid hormones, catalyzing the inner ring deiodination of thyroxine (T(4)) to reverse triiodothyronine (rT(3)) and (T(3)) to 3, 3'-diiodothyronine (T(2)), both of which are biologically inactive. Its physiologic role and pathophysiologic effects in humans can be understood in this context. D3 activity in the normal uteroplacental unit regulates the transfer of maternal thyroid hormone to the fetus and, in patients with consumptive hypothyroidism, the rapid destruction of circulating thyroid hormone by tumoral D3 can produce severe hypothyroxinemia. D3 is expressed in multiple fetal structures, but the uterine endometrium and the placenta are the only normal tissues known to express high levels of D3 activity in the mature human. D3 has also been found in vascular anomalies, in human brain tumors, and in some malignant cell lines. These data have led to the categorization of D3 as an oncofetal protein, but recent data indicate that postnatal expression can be reactivated in normal tissues during critical illness and other pathologic conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131330     DOI: 10.1089/thy.2005.15.875

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  24 in total

1.  Identification of differentially expressed genes associated with differential body size in mandarin fish (Siniperca chuatsi).

Authors:  Changxu Tian; Ling Li; Xu-Fang Liang; Shan He; Wenjie Guo; Liyuan Lv; Qingchao Wang; Yi Song
Journal:  Genetica       Date:  2016-07-08       Impact factor: 1.082

Review 2.  Reawakened interest in type III iodothyronine deiodinase in critical illness and injury.

Authors:  Stephen A Huang; Antonio C Bianco
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-01-22

Review 3.  Paradigms of Dynamic Control of Thyroid Hormone Signaling.

Authors:  Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

4.  Myocardial Induction of Type 3 Deiodinase in Dilated Cardiomyopathy.

Authors:  Ari J Wassner; Rebecca H Jugo; David M Dorfman; Robert F Padera; Michelle A Maynard; Ann M Zavacki; Patrick Y Jay; Stephen A Huang
Journal:  Thyroid       Date:  2017-04-05       Impact factor: 6.568

5.  Non-Thyroidal Illness Syndrome in Critically Ill Children: Prognostic Value and Impact of Nutritional Management.

Authors:  An Jacobs; Inge Derese; Sarah Vander Perre; Esther van Puffelen; Sören Verstraete; Lies Pauwels; Sascha Verbruggen; Pieter Wouters; Lies Langouche; Gonzalo Garcia Guerra; Koen Joosten; Ilse Vanhorebeek; Greet Van den Berghe
Journal:  Thyroid       Date:  2019-03-11       Impact factor: 6.568

6.  Halogenated phenolic contaminants inhibit the in vitro activity of the thyroid-regulating deiodinases in human liver.

Authors:  Craig M Butt; Dongli Wang; Heather M Stapleton
Journal:  Toxicol Sci       Date:  2011-05-11       Impact factor: 4.849

Review 7.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

8.  Consumptive hypothyroidism resulting from hepatic vascular tumors in an athyreotic adult.

Authors:  David Howard; Francisco G La Rosa; Stephen Huang; Domenico Salvatore; Michelle Mulcahey; Jennifer Sang-Lee; Michael Wachs; Joshua P Klopper
Journal:  J Clin Endocrinol Metab       Date:  2011-04-20       Impact factor: 5.958

Review 9.  Minireview: 3-Iodothyronamine (T1AM): a new player on the thyroid endocrine team?

Authors:  Thomas S Scanlan
Journal:  Endocrinology       Date:  2008-12-30       Impact factor: 4.736

10.  The enzymatic activity of type 1 iodothyronine deiodinase (D1) is low in liver hemangioma: a preliminary study.

Authors:  Oskar Kornasiewicz; Marcin Debski; Marta Stepnowska; Anna Szałas; Ewa Bar-Andziak; Marek Krawczyk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-01-05       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.